Linli Hu, Jieqiang Lv, Qianhong Ma, Xiujuan Chen, Xiaohong Wang, Xiaoyan Liang, Dingfei Xu, Yanping Li, Yuanhua Huang, Lina Hu, Xiaohui Deng, Jing Wei, Feng Zhou, Songying Zhang, Jie Wang, Fang Ma, Yingpu Sun
RESEARCH QUESTION: Are QL1012 and Gonal-f® equivalent in women undergoing ovarian stimulation for assisted reproductive technology (ART)? DESIGN: This multicentre, randomized, assessor-blinded, phase-three trial was conducted at 13 centres in China. Eligible patients were infertile women; age 20-39 years; body mass index 18-30 kg/m2 ; regular menstrual cycles; and indication for ART. After successful pituitary downregulation, patients were randomly assigned (1:1) to receive QL1012 or Gonal-f®, stratified by age (initial dose of 75-150 IU for women younger than 30 years, 150-225 IU for women aged 30-34 years and 225-300 IU for women aged ≥35 years, subcutaneously, once daily)...
October 17, 2022: Reproductive Biomedicine Online